GlassScriptPhysician profile
Ganesh Shanmugam
NPI 1215148200
$5,275.06
in general payments reported to CMS, 2019-2025
27 companies · $1,028 in 2025
The $1,028 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $378 · 2021: $695 · 2022: $765 · 2023: $987 · 2024: $772 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.05 |
| Education | $303.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,104.42 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $646.90 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $634.25 | 2019-2025 | |
| Alk-Abello, INC | $424.15 | 2020-2023 | Grastek, Odactra, Ragwitek |
| Takeda Pharmaceuticals U.S.A., INC. | $324.85 | 2021-2025 | Cuvitru, Takhzyro |
| Amgen INC. | $289.15 | 2021-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $269.97 | 2023-2024 | |
| Genentech USA, INC. | $267.55 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $253.55 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $178.61 | 2019-2025 | Dupixent |
| Paratek Pharmaceuticals, INC. | $124.99 | 2023 | Nuzyra |
| Kaleo, INC. | $122.44 | 2021-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $90.63 | 2025 | Neffy |
| Optinose US, INC. | $77.12 | 2019-2021 | |
| Csl Behring | $73.13 | 2025 | Hizentra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $59.32 | 2019 | |
| Organon LLC | $57.71 | 2025 | |
| Atricure, INC. | $50.40 | 2024 | |
| Merck Sharp & Dohme LLC | $36.93 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $34.31 | 2021 | |
| Covis Pharma Gmbh | $33.30 | 2022 | |
| Galderma Laboratories, L.P. | $24.60 | 2025 | Nemluvio |
| Incyte Corporation | $22.68 | 2022 | |
| Pfizer INC. | $21.36 | 2023 | |
| Blueprint Medicines Corporation | $18.35 | 2023 | |
| New World Medical,INC. | $18.25 | 2020 | |
| Hospira, INC. | $16.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ganesh Shanmugam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.